CN113826815A - Dietary fiber composite powder for balancing blood sugar and preparation method thereof - Google Patents
Dietary fiber composite powder for balancing blood sugar and preparation method thereof Download PDFInfo
- Publication number
- CN113826815A CN113826815A CN202111144436.4A CN202111144436A CN113826815A CN 113826815 A CN113826815 A CN 113826815A CN 202111144436 A CN202111144436 A CN 202111144436A CN 113826815 A CN113826815 A CN 113826815A
- Authority
- CN
- China
- Prior art keywords
- parts
- oat
- fiber
- raw materials
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 55
- 239000000843 powder Substances 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 45
- 210000004369 blood Anatomy 0.000 title claims abstract description 45
- 239000002131 composite material Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 8
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 44
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 32
- 239000000835 fiber Substances 0.000 claims abstract description 32
- 241000209140 Triticum Species 0.000 claims abstract description 24
- 235000021307 Triticum Nutrition 0.000 claims abstract description 24
- 235000019895 oat fiber Nutrition 0.000 claims abstract description 24
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 22
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims abstract description 22
- 239000001259 polydextrose Substances 0.000 claims abstract description 22
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 22
- 229940035035 polydextrose Drugs 0.000 claims abstract description 22
- 229920001353 Dextrin Polymers 0.000 claims abstract description 13
- 239000004375 Dextrin Substances 0.000 claims abstract description 13
- 235000019425 dextrin Nutrition 0.000 claims abstract description 13
- 229940038580 oat bran Drugs 0.000 claims abstract description 13
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 12
- 229920002752 Konjac Polymers 0.000 claims abstract description 12
- 239000000252 konjac Substances 0.000 claims abstract description 12
- 235000010485 konjac Nutrition 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 8
- 239000005017 polysaccharide Substances 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims description 57
- 238000002156 mixing Methods 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 27
- 238000005303 weighing Methods 0.000 claims description 27
- 238000004806 packaging method and process Methods 0.000 claims description 24
- 238000007789 sealing Methods 0.000 claims description 15
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 10
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 10
- 229920002498 Beta-glucan Polymers 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000007613 environmental effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000010923 batch production Methods 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 238000007639 printing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 4
- 208000004104 gestational diabetes Diseases 0.000 abstract description 13
- 241001312219 Amorphophallus konjac Species 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000010835 comparative analysis Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 208000003107 Premature Rupture Fetal Membranes Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 108091005995 glycated hemoglobin Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000032943 Fetal Distress Diseases 0.000 description 2
- 206010016855 Foetal distress syndrome Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 2
- 201000006346 Neonatal Jaundice Diseases 0.000 description 2
- 206010028923 Neonatal asphyxia Diseases 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000006241 metabolic reaction Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019659 mouth feeling Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/115—Cereal fibre products, e.g. bran, husk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of dietary fibers, and discloses dietary fiber composite powder for balancing blood sugar, which comprises water-insoluble dietary fibers, water-soluble dietary fibers, non-starch polysaccharides and monosaccharides, wherein the water-insoluble dietary fibers comprise oat bran powder, oat fibers and wheat fibers, the water-soluble dietary fibers comprise polydextrose and resistant dextrin, the non-starch polysaccharides comprise purified konjac powder and oat beta-glucose, and the monosaccharides are tagatose. The dietary fiber composite powder prepared by the invention is composed of oat bran powder, polydextrose, resistant dextrin, purified konjac powder, oat fiber, wheat fiber, oat beta-glucose and tagatose, and is multi-dimensional dietary fiber prepared by strict scientific proportioning and accurate proportion, so that the content and basic functions of the dietary fiber are greatly improved and amplified, and the multi-dimensional combined formula promotes the effective utilization of the dietary fiber by a human body and effectively controls the gestational blood sugar level of a gestational diabetes patient.
Description
Technical Field
The invention relates to the technical field of dietary fiber, in particular to dietary fiber composite powder for balancing blood sugar and a preparation method thereof.
Background
Diabetes is a chronic metabolic disorder caused by the interaction of environmental factors and genetic defects. By 2016, about 1.1 hundred million diabetes patients exist in China according to the statistics of the world health organization, and the number of the global diabetes patients is estimated to increase to 6.42 hundred million in 2040 years, which seriously harms the health of the Chinese people. Gestational Diabetes Mellitus (GDM) is one of the common complications during pregnancy, with the incidence of GDM increasing from 2.7% to 5.6% between 10 years, respectively. Data show that the incidence rate of GDM in China is up to 18.9% in 2014, and the incidence rate is increased year by year, so that the GDM has become a great threat to the health of mothers and infants. GDM increases the risk of short-term and long-term bad outcomes of mothers and babies, and poses serious threats to the safety of mothers and babies. It is easy to cause the complicated pregnancy hypertension, the excessive amniotic fluid, the premature rupture of fetal membranes, infection, the difficult delivery of shoulders, the cesarean section, the older than fetus, the premature delivery and the serious malformation of newborn babies and other bad maternal and infant fatalities. Increasing the risk of postpartum type 2 diabetes and future chronic diseases of the fetus. Nutritional dietary intervention is a fundamental and important measure in the treatment of gestational diabetic patients.
The gynecological science division of the Chinese medical society and the perinatal medical division of the Chinese medical society jointly make the guidelines for diagnosis and treatment of gestational diabetes (2014/2018/2020) and simultaneously emphasize that: the dietary fiber has the functions of controlling the postprandial blood sugar rising degree, improving the glucose tolerance and reducing the blood cholesterol, and the recommended daily intake of 25-30 g. The dietary fiber intake of residents in China has a great difference with the national and foreign academic societies, guidelines and consensus recommendation standards, and the daily diet cannot meet the requirements, so that purified dietary fiber preparations need to be additionally supplemented.
International authoritative journal Lancet: high dietary fiber intake (35-39 g/d) can reduce morbidity and mortality risk of chronic diseases. Compared with the population with the lowest dietary fiber intake, the incidence of coronary heart disease, stroke, type 2 diabetes and colorectal cancer of the population with high intake is reduced by 16-24 percent; the total death rate is also reduced by 15 to 30 percent.
Various dietary fiber drinks appear in the market at present, but the drinks are not easy to be absorbed by human bodies generally, can not effectively reduce the blood sugar and the blood fat content, and have no obvious effect on gestational diabetes patients.
Disclosure of Invention
The invention aims to provide dietary fiber composite powder for balancing blood sugar and a preparation method thereof, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
the dietary fiber composite powder for balancing the blood sugar comprises water-insoluble dietary fibers, water-soluble dietary fibers, non-starch polysaccharides and monosaccharides, wherein the water-insoluble dietary fibers comprise oat bran powder, oat fibers and wheat fibers, the water-soluble dietary fibers comprise polydextrose and resistant dextrin, the non-starch polysaccharides comprise purified konjac refined powder and oat beta-glucose, and the monosaccharides are tagatose and consist of the following components in parts by weight:
90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose.
A preparation method of dietary fiber composite powder for balancing blood sugar comprises the following steps:
s1, raw material pretreatment: according to the current batch production plan, corresponding raw materials are taken from a raw material warehouse, an outer bag is taken off in a bag-off room, the surface of an inner bag of the raw materials is sprayed with disinfecting alcohol for wiping and disinfection, a label is pasted and then is transmitted to a batching room, the raw materials are screened in the batching room, and corresponding raw material information can be recorded through the label;
s2, raw material weighing and batching, and control of parameters of the weighing and batching link: controlling the environmental temperature below 25 ℃ and the humidity below 65%, then weighing 90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose, sealing immediately after all the raw materials are used, preventing oxidation and moisture, and weighing the raw materials;
s3, mixing the raw materials: accurately weighing raw materials with the proportion of less than 5% from the raw materials obtained in the step S2 to prepare a small material, fully mixing the small materials according to gradient, wherein the raw materials with the content of less than 5% comprise oat fiber, wheat fiber, oat beta-glucan and tagatose, and adding the small material and all the rest materials into a mixer for mixing;
s4, sterilizing and packaging: sterilizing the whole cleaning workshop and related equipment facilities and tools, transferring materials through a pipeline, and packaging and tying the materials by using a PE bag after metal detection; conveying the tea leaves into a purification workshop, and quantitatively filling the tea leaves by using an automatic packaging machine, wherein the filling weight is executed according to the net content of each bag of 15g, and the error of each bag is controlled within +/-0.1 g; according to the characteristics of the packaging bag film, the packaging bag is sealed by using an automatic packaging machine, so that the sealing is tight and attractive;
s5, conveying the small bag products to an outer packing workshop for outer packing, taking 20 bags to pack into a box, putting the box into a specification, printing information such as production date, quality guarantee period and the like, then attaching a sealing label and an anti-counterfeiting label, and then boxing, sealing and packaging the products; then warehousing the finished product and carrying out ex-factory inspection; and finally, delivering the finished product out of the warehouse.
As a still further scheme of the invention: the fiber content of the oat fiber and the wheat fiber is more than 90%, and the fiber length is 200 microns.
As a still further scheme of the invention: and in the step S1, a 40-mesh stainless steel sieve is adopted for screening the raw materials, and the raw materials which do not reach 40 meshes need to be crushed and then screened by a 40-mesh sieve.
As a still further scheme of the invention: when the ratio of the raw materials in the step S2 is less than 1%, the precision of the electronic scale used for weighing is 0.1g, and the precision of the electronic scale used for weighing the rest of the raw materials is 10 g.
As a still further scheme of the invention: and in the step S4, the temperature of the purification workshop is controlled to be below 25 ℃, the humidity is controlled to be below 65%, and the sealing temperature of the automatic packaging machine is controlled to be 115-125 ℃.
As a still further scheme of the invention: the gradient mixing mode in the step S3 includes the following steps:
s31, taking 12 parts of oat fiber and 10 parts of wheat fiber from the weighed and standby raw materials, pouring 22 parts of oat fiber and wheat fiber into a small mixer for fully mixing, weighing 28 parts of polydextrose after mixing for 15 minutes, pouring the polydextrose into 22 parts of premix for continuously and fully mixing for 10 minutes, bagging after uniformly mixing to obtain 50 parts of premix I;
s32, taking 8 parts of oat beta-glucan and 4 parts of tagatose from the weighed and standby raw materials, pouring 12 parts of oat beta-glucan and 4 parts of tagatose into a small mixer for fully mixing, after mixing for 10 minutes, weighing 18 parts of polydextrose, pouring 12 parts of premix, continuing to fully mix for 10 minutes, and bagging after uniform mixing to obtain premix II, wherein the total amount of the premix is 30 minutes;
s33, putting 80 parts of materials obtained in the S31 and S32 steps and the rest 220 parts of materials into a large three-dimensional mixer, uniformly mixing for 50 minutes, sieving by a vibrating screen with 20 meshes, and conveying to an inner package filling room through a material conveying pipeline.
Compared with the prior art, the invention has the beneficial effects that:
the dietary fiber composite powder prepared by the invention is composed of oat bran powder, polydextrose, resistant dextrin, purified konjac powder, oat fiber, wheat fiber, oat beta-glucose and tagatose, and is multi-dimensional dietary fiber prepared by strict scientific proportion and accurate proportion, so that the content and basic functions of the dietary fiber are greatly improved and amplified, and the multi-dimensional combined formula promotes the effective utilization of the dietary fiber by a human body, can regulate insulin, improve the glucose tolerance of an organism, slow down the glucose absorption, inhibit the postprandial blood glucose rise, inhibit the activity of hydrolase, reduce the activity of metabolic enzyme, slow down the glucose generation rate, influence the blood glucose metabolic reaction and effectively control the blood glucose level of a gestational diabetes patient.
Detailed Description
In the embodiment of the invention, the dietary fiber composite powder for balancing blood sugar comprises water-insoluble dietary fiber, water-soluble dietary fiber, non-starch polysaccharide and monosaccharide, wherein the water-insoluble dietary fiber comprises oat bran powder, oat fiber and wheat fiber, the water-soluble dietary fiber comprises polydextrose and resistant dextrin, the non-starch polysaccharide comprises purified konjac powder and oat beta-glucose, the monosaccharide is tagatose, the polydextrose and the resistant dextrin belong to high-quality soluble dietary fiber, and the high-quality soluble dietary fiber composite powder can play roles in coating grease, reducing cholesterol, increasing intestinal probiotics, promoting mineral absorption, stabilizing blood sugar and the like, and is an important supplement of the non-soluble dietary fiber; the oat bran powder is a high-fiber substance containing a large amount of non-soluble dietary fiber and soluble dietary fiber, and the tagatose can obviously inhibit the blood sugar rise of a diabetic patient caused by the ingestion of glucose; the oat beta-glucan has good repairing effect on liver and kidney tissue lesion complicated by diabetes, can effectively reduce the decomposition of liver glycogen so as to reduce blood sugar, and consists of the following components in parts by weight:
90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose.
A preparation method of dietary fiber composite powder for balancing blood sugar comprises the following steps:
s1, raw material pretreatment: according to the current batch production plan, corresponding raw materials are taken from a raw material warehouse, an outer bag is taken off in a bag-off room, the surface of an inner bag of the raw materials is sprayed with disinfecting alcohol for wiping and disinfection, a label is pasted and then is transmitted to a batching room, the raw materials are screened in the batching room, and corresponding raw material information can be recorded through the label;
s2, raw material weighing and batching, and control of parameters of the weighing and batching link: controlling the environmental temperature below 25 ℃ and the humidity below 65%, then weighing 90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose, sealing immediately after all the raw materials are used, preventing oxidation and moisture, and weighing the raw materials;
s3, mixing the raw materials: accurately weighing raw materials with the proportion of less than 5% from the raw materials obtained in the step S2 to prepare a small material, fully mixing the small materials according to gradient, wherein the raw materials with the content of less than 5% comprise oat fiber, wheat fiber, oat beta-glucan and tagatose, and adding the small material and all the rest materials into a mixer for mixing;
s4, sterilizing and packaging: sterilizing the whole cleaning workshop and related equipment facilities and tools, transferring materials through a pipeline, and packaging and tying the materials by using a PE bag after metal detection; conveying the tea leaves into a purification workshop, and quantitatively filling the tea leaves by using an automatic packaging machine, wherein the filling weight is executed according to the net content of each bag of 15g, and the error of each bag is controlled within +/-0.1 g; according to the characteristics of the packaging bag film, the packaging bag is sealed by using an automatic packaging machine, so that the sealing is tight and attractive;
s5, conveying the small bag products to an outer packing workshop for outer packing, taking 20 bags to pack into a box, putting the box into a specification, printing information such as production date, quality guarantee period and the like, then attaching a sealing label and an anti-counterfeiting label, and then boxing, sealing and packaging the products; then warehousing the finished product and carrying out ex-factory inspection; and finally, delivering the finished product out of the warehouse.
Preferably, the fiber content of the oat fiber and the wheat fiber is more than 90 percent, the fiber length is 200 micrometers, the mouth feeling of the product is greatly improved, and meanwhile, the stimulation and the uncomfortable feeling of the high-content fiber product to intestines and stomach are reduced to the minimum.
Preferably, the raw material in the step S1 is sieved by a 40-mesh stainless steel sieve, and the raw material which does not reach 40 meshes is crushed and sieved by a 40-mesh sieve.
Preferably, when the ratio of the raw material in the step S2 is less than 1%, the precision of the electronic scale used for weighing is 0.1g, and the precision of the electronic scale used for weighing the rest of the raw material is 10 g.
Preferably, the temperature of the cleaning shop in the step S4 is controlled to be below 25 ℃, the humidity is controlled to be below 65%, and the sealing temperature of the automatic packaging machine is controlled to be 115-125 ℃.
Preferably, the gradient mixing manner in the step S3 includes the following steps:
s31, taking 12 parts of oat fiber and 10 parts of wheat fiber from the weighed and standby raw materials, pouring 22 parts of oat fiber and wheat fiber into a small mixer for fully mixing, weighing 28 parts of polydextrose after mixing for 15 minutes, pouring the polydextrose into 22 parts of premix for continuously and fully mixing for 10 minutes, bagging after uniformly mixing to obtain 50 parts of premix I;
s32, taking 8 parts of oat beta-glucan and 4 parts of tagatose from the weighed and standby raw materials, pouring 12 parts of oat beta-glucan and 4 parts of tagatose into a small mixer for fully mixing, after mixing for 10 minutes, weighing 18 parts of polydextrose, pouring 12 parts of premix, continuing to fully mix for 10 minutes, and bagging after uniform mixing to obtain premix II, wherein the total amount of the premix is 30 minutes;
s33, putting 80 parts of materials obtained in the S31 and S32 steps and the rest 220 parts of materials into a large three-dimensional mixer, uniformly mixing for 50 minutes, sieving by a vibrating screen with 20 meshes, and conveying to an inner package filling room through a material conveying pipeline.
To better illustrate the technical effects of the present invention, the following examples are given:
100 gestational diabetes patients are selected and randomly divided into two groups, wherein each group comprises 50 patients, and one group is taken as an embodiment group, the dietary fiber composite powder prepared by the invention is taken twice a day, 1 bag is taken each time, and the powder is taken 15 minutes before meals by adding about 150mL of warm boiled water; the other group is used as a comparative group for carrying out conventional nutrition treatment, the fasting blood sugar content of the two groups of patients before treatment is respectively (5.41 +/-1.92) mmol/L and (5.52 +/-1.90) mmol/L, and the differences are not statistically significant and are comparable after statistical treatment;
first, fasting blood glucose, postprandial 1h blood glucose and postprandial 2h blood glucose contents (unit: mmol/L) of patients of the example group and the comparative example group before and after treatment were measured, respectively, and recorded in the following Table 1 for comparative analysis, respectively.
TABLE 1 comparison of blood glucose levels
From the analysis of table 1: the fasting blood sugar, the blood sugar after 1 hour after meal and the blood sugar after 2 hours after meal of the two groups of patients are all lower than the blood sugar before treatment; after treatment, fasting blood glucose, blood glucose after 1 hour after meal and blood glucose after 2 hours after meal of the patients in the example group are all lower than those in the comparative example group, and further, it can be concluded that: the invention can regulate insulin, improve glucose tolerance of organism, slow down glucose absorption and inhibit postprandial blood sugar rise.
Continuously performing follow-up survey on the patients of the example group and the comparative group, respectively observing the conditions of the patients of the example group and the comparative group, recording the number and the ratio of premature rupture of fetal membranes, fetal distress, premature birth and birth canal laceration of the patients, recording the number and the ratio of giant infants, neonatal asphyxia and hyperbilirubinemia in the neonates in the following table 2, recording the number and the ratio of giant infants, neonatal asphyxia and hyperbilirubinemia in the neonates in the following table 3, and respectively performing comparative analysis.
TABLE 2 comparison of parturient outcomes (ratio: 100%)
| Group of | Premature rupture of fetal membranes | Fetal distress | Premature delivery | Laceration of birth canal |
| Group of embodiments | 6(12.00％) | 6(12.00％) | 5(10.00％) | 11(22.00％) |
| Comparative example group | 14(28.00％) | 9(18.00％) | 8(16.00％) | 13(26.00％) |
| χ2 | 4.000 | 0.706 | 0.796 | 0.219 |
| P | 0.046 | 0.401 | 0.372 | 0.640 |
TABLE 3 neonatal outcome comparison [ examples (%) ]
| Group of | Giant | Asphyxia of newborn | Hyperbilirubinemia |
| Group of embodiments | 4(8.00) | 0(0％) | 4(8.00％) |
| Comparative example group | 7(14.00) | 5(10.00％) | 19(38.00％) |
| χ2 | 0.919 | 3.368 | 12.705 |
| P | 0.338 | 0.067 | <0.001 |
From the analysis of tables 2 and 3: the patients of the example group had a lower incidence of premature rupture of membranes and hyperbilirubinemia of newborns than the patients of the comparative example group. Further, it can be found that: the invention can improve the poor pregnancy outcome in perinatal period.
And thirdly, observing various glycolipid metabolism indexes of the patients in the example group and the patients in the comparative example group respectively, wherein the indexes comprise: triglyceride (symbol: TG, unit: mmol/L), total cholesterol (symbol: TC, unit: mmol/L), free fatty acid (symbol: FFA), fibrinogen (symbol: FBG, unit: mmol/L), glycated hemoglobin (symbol: HbAlc, unit: 100%), and recorded in the following Table 4, respectively, for comparative analysis.
TABLE 4 glycolipid metabolism index comparison
From the analysis of table 4: the patients in the example group and the patients in the comparative example group both significantly reduced the fasting blood glucose and the glycated hemoglobin before and after the intervention, and the patients in the example group significantly reduced the fasting blood glucose and the glycated hemoglobin before and after the intervention, and the patients in the comparative example group, further resulted in: the invention can inhibit the activity of hydrolase, reduce the activity of metabolic enzyme, slow down the production rate of glucose and influence the metabolic reaction of blood sugar.
And fourthly, observing the onset of the diabetes of the patients in the example group and the patients in the comparative example group after delivery, recording the number and the proportion of the onset and the non-onset, recording the number and the proportion in the following table 5, and performing comparative analysis respectively.
TABLE 5 comparison of diabetes incidence
| Group of | Onset of disease | Not onset of disease |
| Group of embodiments | 1(2.00％) | 49(98.00％) |
| Comparative example group | 12(24.00％) | 38(76.00％) |
| χ2 | 6.317 | 6.317 |
| P | 0.000 | 0.000 |
From the analysis of table 5: the postpartum diabetes incidence of the patients of the example group was 2.00%, the postpartum diabetes incidence of the patients of the comparative example group was 24.00%, and the postpartum diabetes incidence of the patients of the example group was significantly lower than that of the comparative example, thereby yielding: the invention is beneficial to reducing the morbidity risk of postpartum diabetes.
In summary, it can be found that: in intervention of gestational diabetes, the dietary fiber composite powder prepared by the invention has good clinical effect and can effectively control gestational blood sugar level of patients with gestational diabetes.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention are equivalent to or changed within the technical scope of the present invention.
Claims (7)
1. The dietary fiber composite powder for balancing the blood sugar comprises water-insoluble dietary fibers, water-soluble dietary fibers, non-starch polysaccharides and monosaccharides, and is characterized in that the water-insoluble dietary fibers comprise oat bran powder, oat fibers and wheat fibers, the water-soluble dietary fibers comprise polydextrose and resistant dextrin, the non-starch polysaccharides comprise purified konjac refined powder and oat beta-glucose, and the monosaccharides are tagatose and consist of the following components in parts by weight:
90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose.
2. The preparation method of the dietary fiber composite powder for balancing blood sugar, which is used for realizing the balance of the blood sugar in the claim 1, is characterized by comprising the following steps:
s1, raw material pretreatment: according to the current batch production plan, corresponding raw materials are taken from a raw material warehouse, an outer bag is taken off in a bag-off room, the surface of an inner bag of the raw materials is sprayed with disinfecting alcohol for wiping and disinfection, a label is pasted and then is transmitted to a batching room, the raw materials are screened in the batching room, and corresponding raw material information can be recorded through the label;
s2, raw material weighing and batching, and control of parameters of the weighing and batching link: controlling the environmental temperature below 25 ℃ and the humidity below 65%, then weighing 90 parts of oat bran powder, 86 parts of polydextrose, 60 parts of resistant dextrin, 30 parts of purified konjac powder, 12 parts of oat fiber, 10 parts of wheat fiber, 8 parts of oat beta-glucose and 4 parts of tagatose, sealing immediately after all the raw materials are used, preventing oxidation and moisture, and weighing the raw materials;
s3, mixing the raw materials: accurately weighing raw materials with the proportion of less than 5% from the raw materials obtained in the step S2 to prepare a small material, fully mixing the small materials according to gradient, wherein the raw materials with the content of less than 5% comprise oat fiber, wheat fiber, oat beta-glucan and tagatose, and adding the small material and all the rest materials into a mixer for mixing;
s4, sterilizing and packaging: sterilizing the whole cleaning workshop and related equipment facilities and tools, transferring materials through a pipeline, and packaging and tying the materials by using a PE bag after metal detection; conveying the tea leaves into a purification workshop, and quantitatively filling the tea leaves by using an automatic packaging machine, wherein the filling weight is executed according to the net content of each bag of 15g, and the error of each bag is controlled within +/-0.1 g; according to the characteristics of the packaging bag film, the packaging bag is sealed by using an automatic packaging machine, so that the sealing is tight and attractive;
s5, conveying the small bag products to an outer packing workshop for outer packing, taking 20 bags to pack into a box, putting the box into a specification, printing information such as production date, quality guarantee period and the like, then attaching a sealing label and an anti-counterfeiting label, and then boxing, sealing and packaging the products; then warehousing the finished product and carrying out ex-factory inspection; and finally, delivering the finished product out of the warehouse.
3. A dietary fiber composite powder for balancing blood sugar according to claim 1, wherein the fiber content of the oat fiber and the wheat fiber are both more than 90%, and the fiber length is 200 microns.
4. The method for preparing dietary fiber composite powder for balancing blood sugar as claimed in claim 2, wherein the raw material in the step S1 is sieved with a 40-mesh stainless steel sieve, and the raw material which does not reach 40 meshes is pulverized and sieved with a 40-mesh sieve.
5. The method for preparing dietary fiber composite powder for balancing blood sugar according to claim 2, wherein when the ratio of the raw materials in the step of S2 is less than 1%, the precision of the electronic scale used for weighing is 0.1g, and the precision of the electronic scale used for weighing the rest raw materials is 10 g.
6. The method for preparing dietary fiber composite powder for balancing blood sugar according to claim 2, wherein the temperature of the cleaning shop in the step S4 is controlled to be below 25 ℃, the humidity is controlled to be below 65%, and the sealing temperature of the automatic packaging machine is controlled to be 115-125 ℃.
7. The method for preparing dietary fiber composite powder for balancing blood sugar as claimed in claim 1, wherein the gradient mixing manner in the step of S3 comprises the following steps:
s31, taking 12 parts of oat fiber and 10 parts of wheat fiber from the weighed and standby raw materials, pouring 22 parts of oat fiber and wheat fiber into a small mixer for fully mixing, weighing 28 parts of polydextrose after mixing for 15 minutes, pouring the polydextrose into 22 parts of premix for continuously and fully mixing for 10 minutes, bagging after uniformly mixing to obtain 50 parts of premix I;
s32, taking 8 parts of oat beta-glucan and 4 parts of tagatose from the weighed and standby raw materials, pouring 12 parts of oat beta-glucan and 4 parts of tagatose into a small mixer for fully mixing, after mixing for 10 minutes, weighing 18 parts of polydextrose, pouring 12 parts of premix, continuing to fully mix for 10 minutes, and bagging after uniform mixing to obtain premix II, wherein the total amount of the premix is 30 minutes;
s33, putting 80 parts of materials obtained in the S31 and S32 steps and the rest 220 parts of materials into a large three-dimensional mixer, uniformly mixing for 50 minutes, sieving by a vibrating screen with 20 meshes, and conveying to an inner package filling room through a material conveying pipeline.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111144436.4A CN113826815A (en) | 2021-09-28 | 2021-09-28 | Dietary fiber composite powder for balancing blood sugar and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111144436.4A CN113826815A (en) | 2021-09-28 | 2021-09-28 | Dietary fiber composite powder for balancing blood sugar and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113826815A true CN113826815A (en) | 2021-12-24 |
Family
ID=78967142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111144436.4A Pending CN113826815A (en) | 2021-09-28 | 2021-09-28 | Dietary fiber composite powder for balancing blood sugar and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113826815A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114680340A (en) * | 2022-04-26 | 2022-07-01 | 王路 | Formula of polysaccharide multi-dimensional dietary fiber composite powder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104171802A (en) * | 2014-08-18 | 2014-12-03 | 海南康虹医药科技开发有限公司 | Dietary fiber composition |
| CN108371285A (en) * | 2018-02-24 | 2018-08-07 | 苏维康 | Fine rehabilitation side's Fiber Metabolism adjusts nutritional meal replacement powder |
-
2021
- 2021-09-28 CN CN202111144436.4A patent/CN113826815A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104171802A (en) * | 2014-08-18 | 2014-12-03 | 海南康虹医药科技开发有限公司 | Dietary fiber composition |
| CN108371285A (en) * | 2018-02-24 | 2018-08-07 | 苏维康 | Fine rehabilitation side's Fiber Metabolism adjusts nutritional meal replacement powder |
Non-Patent Citations (1)
| Title |
|---|
| 王莹，等: "膳食中添加食物纤维改善血糖指数的研究", 《医学研究杂志》, vol. 45, no. 10, pages 39 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114680340A (en) * | 2022-04-26 | 2022-07-01 | 王路 | Formula of polysaccharide multi-dimensional dietary fiber composite powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105581302B (en) | Jelly for providing energy required by parturient childbirth and preparation method thereof | |
| CN103284039A (en) | Weight-reducing composition and preparation method thereof | |
| CN102754728B (en) | Blueberry, black fungus and carrot composite jelly and preparation method thereof | |
| CN104322630B (en) | Konjaku soda cracker and its production technology | |
| CN101422239B (en) | Combined partner capable of increasing edible rice, flour nutrition | |
| CN101618029B (en) | Soft capsule with function of improving memory and preparation technology thereof | |
| CN106880058A (en) | A kind of Sugarless syrups and preparation method thereof | |
| CN105211999A (en) | A kind of hypoglycemia patient oat beverage and preparation method thereof | |
| CN101606681A (en) | A kind of composite solid sweetener | |
| CN113826815A (en) | Dietary fiber composite powder for balancing blood sugar and preparation method thereof | |
| CN103975991A (en) | Healthcare mulberry anthocyanidin biscuit | |
| CN101703227A (en) | Lactogenic soup | |
| CN111096404A (en) | Selenium-rich highland barley milk beverage and preparation method thereof | |
| CN105901148A (en) | Low glycemic index oat-milk composition and preparation method thereof | |
| CN105685904B (en) | Jelly for parturient childbirth and preparation method thereof | |
| CN102669766B (en) | Method for preparing mixed fruit and vegetable juice drink consisting of carrots, oranges and apples and containing oat Beta-glucosan | |
| CN102000082B (en) | Medicament or health care food with memory strengthening effect | |
| CN103281914B (en) | Purification of soluble mannan compositions and using method thereof for dietary supplement | |
| CN102511858A (en) | Thickened red jujube pulp suitable for being taken by pregnant women and manufacturing technology of same | |
| CN101223966A (en) | Preparing method of kiwi series food | |
| CN103665182A (en) | Acid degradation preparation method of konjac glucomannan | |
| CN116439368B (en) | Nutritional composition for pregnant women and preparation method thereof | |
| CN113170880A (en) | Bird's nest peptide pregnant woman bird's nest and preparation method thereof | |
| CN101440109B (en) | Method for preparation of functional low polyxylose alcohol | |
| CN104997020A (en) | Compound lactase composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211224 |
|
| RJ01 | Rejection of invention patent application after publication |